MARK G. AGRESTI MD LLC  ·  PALM BEACH, FLORIDA

TRENDING  ·  GLP-1 DRUGS  ·  PSYCHIATRY

Ozempic & Your Mood

What your weight loss doctor isn’t telling you about GLP-1 drugs, your brain, and your mental health.

By Mark G. Agresti, MD  |  Mark G. Agresti MD LLC  |  drmarkagresti.com  |  Palm Beach, Florida  |  April 2026

Ozempic is everywhere in Palm Beach. Wegovy, Mounjaro, Zepbound — the GLP-1 revolution has swept through concierge medicine offices, weight loss clinics, and internists’ waiting rooms across South Florida and beyond. Millions of Americans are now taking these drugs, and the results for weight loss and metabolic health have been, in many cases, remarkable.

But here is what very few prescribers are talking to their patients about: GLP-1 medications do not just act on your gut, your pancreas, and your waistline. They act on your brain. And for a significant subset of patients — particularly those with any personal or family history of depression, anxiety, or other mood disorders — that brain activity can have profound and unexpected psychiatric consequences.

I am Dr. Mark G. Agresti, a psychiatrist in Palm Beach, Florida, and founder of Mark G. Agresti MD LLC. I am writing this article because I am seeing the real-world psychiatric fallout from GLP-1 prescriptions written without any mental health screening — patients who came in for weight loss and left with an unrecognized depressive episode. This is a conversation that needs to happen, and it needs to happen now.

44%

Lower risk of depression in a 95,000-patient semaglutide study — for some users

38%

Lower risk of anxiety disorders among GLP-1 users in the same landmark study

300%

Surge in Google searches for “Ozempic depression” over the past year

1 in 5

Americans has a mental health condition — most receive no psychiatric screening before GLP-1 prescriptions

How Ozempic Gets Into Your Brain

To understand why GLP-1 drugs affect mood, you need to understand what they actually do neurologically. Semaglutide — the active ingredient in Ozempic and Wegovy — is a glucagon-like peptide-1 receptor agonist. It mimics a natural hormone your gut produces after eating, signaling fullness, regulating blood sugar, and slowing digestion. That much is well known.

What is less well known is that GLP-1 receptors are not confined to the gut and pancreas. They are distributed throughout the brain — including in the hypothalamus, the hippocampus, the ventral tegmental area, and the nucleus accumbens. These are not peripheral metabolic regions. These are core centers of mood regulation, emotional memory, stress response, motivation, and — critically — dopamine-driven reward.

When semaglutide activates GLP-1 receptors in the brain’s reward circuitry, it dampens the dopamine response to pleasurable stimuli. That is precisely how it reduces food cravings so effectively. But dopamine does not distinguish between a slice of pizza and an evening with friends, a glass of wine, a favorite hobby, or the feeling of joy at an ordinary moment. When GLP-1 drugs quiet the reward system, they can quiet it across the board.

“GLP-1 receptors are found in brain regions governing mood, motivation, and reward. When these drugs act on those receptors, the psychiatric effects — for better or worse — should surprise no one. What surprises me is how rarely patients are warned.”— Mark G. Agresti, MD  ·  Mark G. Agresti MD LLC  ·  Palm Beach, Florida

The “Ozempic Personality”: What It Really Is

Across social media — Reddit threads, TikTok videos, online patient communities — a term has emerged: “Ozempic personality.” Patients describe feeling emotionally flat. Less reactive. Less interested. Less themselves. Things that used to bring pleasure — food, socializing, sex, hobbies, music — feel muted. Life feels like it is being experienced through a layer of foam.

This is not a social media myth. Clinically, what these patients are describing is anhedonia — the diminished capacity to experience pleasure — which is one of the two cardinal symptoms of major depressive disorder. It is driven by reduced dopamine activity in the brain’s reward pathways, and it is exactly what you would predict from a medication that powerfully suppresses dopamine-mediated reward responses.

Researchers believe the effect may be linked specifically to how GLP-1 medications influence dopamine signaling. By suppressing appetite and food-related cravings, the drugs may also dampen other reward responses — not because the medication is inherently mood-toxic, but because the brain does not have separate dopamine circuits for food versus everything else. The same mechanism that makes Ozempic an effective appetite suppressant may, in vulnerable individuals, tip the neurochemical balance toward a depressive phenotype.

It is worth noting that doctors also report that these effects are not considered widespread, and that for many patients there is no negative mood impact whatsoever. The Ozempic personality phenomenon appears to affect a subset of users — but that subset deserves to be identified before they start the medication, not after they are already suffering.

The Two Sides of the Research: Promise and Caution

The science on GLP-1 drugs and mental health is genuinely two-sided, and intellectual honesty requires presenting both. Here is what the evidence currently shows:

✓ The Promising Findings

• A landmark 2026 study of nearly 95,000 patients found a 44% lower risk of depression and 38% lower risk of anxiety among semaglutide users
• GLP-1 drugs show anti-inflammatory effects in the brain, and neuroinflammation is increasingly linked to depression
• Semaglutide promotes hippocampal neurogenesis — new brain cell growth in the region most critical to mood and memory
• Substance use disorders fell by 47% and hospitalization for mental health conditions dropped 42% among GLP-1 users in large studies
• Weight loss itself, improved metabolic health, and better sleep can produce meaningful mood improvements
• GLP-1 drugs are being actively investigated as adjunct treatments for treatment-resistant depression

! The Risk Findings

• A 2024 Nature cohort study of 300,000+ patients found a slightly increased risk of depression and suicidal ideation in semaglutide users
• 1.2% of all reported GLP-1 side effects in a 2024 review were adverse psychiatric events — depression was the most common, followed by anxiety
• Emotional blunting and anhedonia (“Ozempic personality”) are widely reported in patient communities and are biologically plausible
• The original Ozempic clinical trials did not screen participants for psychiatric history — meaning vulnerable populations were never studied
• The FDA and European Medicines Agency have both launched ongoing reviews of GLP-1 drugs for potential psychiatric side effects
• GLP-1 drugs may be acutely anxiogenic — one preclinical study found anxiety-like behavior immediately after initiation, before mood benefits emerged

The bottom line: for many patients, GLP-1 drugs appear to be mood-neutral or even mood-positive. But for a meaningful subset — particularly those with pre-existing psychiatric vulnerability — these medications can tip the neurochemical balance in a dangerous direction. And because the majority of prescriptions are being written without any psychiatric screening whatsoever, the patients most at risk are the least likely to be identified before problems develop.

Who Is Most at Risk for Psychiatric Side Effects?

History of Depression

Patients with prior depressive episodes are most vulnerable to GLP-1-mediated dopamine disruption, particularly anhedonia and emotional blunting.

Anxiety Disorders

GLP-1 drugs may be acutely anxiogenic in the early weeks of treatment. Those with generalized anxiety or panic disorder warrant careful monitoring at initiation.

Low Dopamine Baseline

Individuals who already have low dopamine function — common in ADHD, chronic fatigue, and certain depressive subtypes — may be particularly susceptible to further reward suppression.

Family Psychiatric History

A strong family history of depression, bipolar disorder, or substance use disorders suggests genetic vulnerability to dopaminergic disruption from GLP-1 exposure.

Rapid Weight Loss

Extremely rapid weight loss can cause nutritional deficiencies — particularly in B vitamins and zinc — that independently worsen mood and cognitive function.

Social Isolation

Patients whose social lives are built around food and dining may find the rewiring of food-related pleasure socially disorienting, which can compound anhedonia into clinical depression.

⚠ Warning Signs to Watch For on GLP-1 Medications

• Feeling emotionally flat, numb, or disconnected from things you used to enjoy
• Loss of pleasure in food, socializing, hobbies, or sex that goes beyond reduced cravings
• Persistent low mood, sadness, or hopelessness that wasn’t present before starting the medication
• Increased anxiety, irritability, or feelings of dread — especially in the first weeks of treatment
• Withdrawal from friends, family, or previously enjoyable activities
• Changes in sleep, energy, or motivation beyond what weight loss alone would explain
• Any thoughts of self-harm or feelings of worthlessness — seek help immediately

What the Weight Loss Clinic Isn’t Asking You

Here is the clinical reality in 2026: GLP-1 medications are being prescribed at extraordinary scale by physicians who are not mental health specialists. Telehealth platforms dispense semaglutide after brief online questionnaires. Concierge medicine and medical weight loss practices — many of them excellent at what they do metabolically — are not equipped to screen for or monitor psychiatric risk.

The original clinical trials for Ozempic and Wegovy excluded patients with a history of depression, suicidal ideation, or other psychiatric conditions. This means the very patients most likely to experience adverse psychiatric effects were never studied. The FDA and European Medicines Agency have both launched ongoing safety reviews precisely because of this gap.

What this means for patients is straightforward: **if you are on a GLP-1 medication and have any history of depression, anxiety, or other mood disorders — or if you are noticing mood changes since starting — you need to be seen by a psychiatrist, not just your weight loss physician.**These are not competing conversations. They are complementary ones. Your weight loss doctor is managing your metabolic health. Your psychiatrist is managing your brain.

The Psychiatrist’s Role in the GLP-1 Era

At Mark G. Agresti MD LLC in Palm Beach, Florida, I am increasingly being consulted by patients who are on GLP-1 medications and experiencing mood changes — sometimes subtle, sometimes severe — that were not anticipated and are not being addressed by their prescribing physician. My role in these cases involves several things.

First, a thorough psychiatric evaluation to determine whether mood changes are directly related to the GLP-1 medication, whether they represent the emergence or recurrence of a primary mood disorder, or whether they are multifactorial — which they often are. Second, a careful assessment of dopamine function, reward sensitivity, and anhedonia. Third, if indicated, targeted treatment — which may involve adjusting the GLP-1 dose, changing formulations, or initiating antidepressant therapy. And fourth, ongoing monitoring as the medication is continued, because psychiatric risk on GLP-1 drugs is not static.

For patients considering GLP-1 medications who have a psychiatric history, a pre-prescription psychiatric consultation is not an obstacle to starting treatment — it is the thing that makes starting treatment safely possible.

“The GLP-1 revolution is genuinely exciting. These drugs are changing lives. But they are brain-active medications, and in 2026, we cannot continue prescribing them at scale without integrating psychiatric oversight for vulnerable patients. That is not cautious — it is responsible medicine.”— Mark G. Agresti, MD  ·  Mark G. Agresti MD LLC  ·  Palm Beach, Florida

Frequently Asked Questions

Can Ozempic cause depression or mood changes?

Yes, in some individuals. GLP-1 medications like Ozempic act on dopamine reward pathways in the brain. Some users experience emotional blunting, reduced motivation, or depressive episodes — particularly those with a pre-existing mental health history. Anyone noticing mood changes on Ozempic should consult a psychiatrist promptly.

What is “Ozempic personality”?

Ozempic personality is a term coined on social media describing a reduced ability to feel pleasure, emotional flatness, or loss of motivation experienced by some GLP-1 drug users. Clinically, this aligns with anhedonia — a core symptom of depression — and is thought to be related to how these drugs influence dopamine signaling in the brain’s reward system.

Does Ozempic help with depression and anxiety?

The research is genuinely promising for many patients. A major 2026 study of nearly 95,000 patients found that semaglutide users had a 44% lower risk of depression and a 38% lower risk of anxiety disorders. However, results are not universal — some individuals, particularly those with pre-existing mood disorders or low dopamine function, may experience worsening symptoms.

Should I stop taking Ozempic if I feel depressed?

Do not stop any prescribed medication without speaking to your doctor first. If you are experiencing mood changes on a GLP-1 medication, the right step is to contact both your prescribing physician and a psychiatrist. There may be options including dose adjustment, formulation change, or treatment for depression that allow you to continue the medication safely.

Who should see a psychiatrist before starting Ozempic?

Anyone with a personal or family history of depression, anxiety, bipolar disorder, ADHD, or other mood disorders should have a psychiatric evaluation before starting a GLP-1 medication. This is not a barrier to treatment — it is the foundation for safe, monitored treatment.

Does Ozempic help with addiction or substance use?

Early research is intriguing. Large studies show substantial reductions in substance use disorders, alcohol-related hospitalizations, and addiction-related sick leave among GLP-1 users. This is consistent with the drug’s effects on dopamine reward pathways. Clinical trials are underway, but this is not yet an approved indication for GLP-1 medications.

Taking Ozempic or Wegovy? Let’s Talk About Your Brain.

If you’re on a GLP-1 medication and noticing mood changes — or if you have a psychiatric history and want to start one safely — Dr. Mark G. Agresti, MD provides expert psychiatric evaluation and monitoring in Palm Beach, Florida.

SCHEDULE A CONSULTATIONMark G. Agresti MD LLC  ·  Palm Beach, Florida  ·  drmarkagresti.com